HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Palliative care flourishing but ‘significant hurdles’ remain John DeRosier
• Should management of a patient’s physical and psychological symptoms be handled by their oncology team?
• Goodbye, Clara Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Survivorship care plans, evidence-based practice and the ‘Triple Aim’ Dorothy Dulko, PhD, ARNP-C, AOCNP, CCRP
• New child care offerings put oncology meetings at the forefront of work-life balance Drew Amorosi
• Off-the-shelf CAR T-cell therapy induces durable remissions in relapsed, refractory B-cell malignancies Mark Leiser
• Encorafenib regimens confer quality-of-life, survival benefit in BRAF V600E-mutant metastatic colorectal cancer John DeRosier
• Outpatient treatment with lisocabtagene maraleucel feasible for certain patients with non-Hodgkin lymphoma Mark Leiser
• Acute GVHD less severe after haploidentical transplant with post-cyclophosphamide prophylaxis Mark Leiser
• Subsequent PFS benefit of apalutamide ‘an indicator of effective early intensive treatment’ in prostate cancer Jennifer R. Southall
• Tucatinib regimen provides ‘unprecedented’ benefit in heavily pretreated HER2-positive breast cancer Mark Leiser
• Children with AML from poor neighborhoods face twofold greater risk for death Alexandra (Sasha) Todak
• Low-dose CT screening linked to reduced lung cancer mortality among current, former smokers Jennifer R. Southall
• Early lenalidomide delays multiple myeloma progression Jennifer R. Southall
• History of dengue infection increases risk for leukemia John DeRosier
• ASCO names refinement of surgical cancer treatment ‘Advance of the Year’ Jennifer R. Southall
• FDA grants orphan drug designation to several hematology/oncology therapies
• FDA finds ‘insufficient evidence’ to link cellphone radiation to cancer
• FDA approves Padcev for urothelial cancer
• Four regimens receive priority review for lung cancer indications
• FDA approves Monoferric injection for iron deficiency anemia
• FDA grants breakthrough therapy designation to APR-246, azacitidine combination for myelodysplastic syndrome
• NIH selects five Lasker Clinical Research Scholars
• Hematopoietic stem cell researcher to receive lecture award
• City of Hope appoints chair of hematology and hematopoietic cell transplantation